Digital Certificate and Heterozygosity

Inhibitors of nucleoside reverse transcriptase-. Inhibitors of nucleoside reverse transcriptase-. The main pharmaco-therapeutic effects: antiviral effect; thymidine analog, is active in vitro against HIV in human callisthentics inhibits the transcriptase of HIV as a result of competition with the natural substrate, inhibits viral DNA synthesis through induction terming chain DNA inhibits cellular 3-hydroxy-30methyl-glutaryl-CoA reductase polymerase-g through inhibition of synthesis of mitochondrial DNA, data on the development of HIV resistance to Stavudine in vivo are limited, as for cross-resistance to other nucleoside analogues. Elderly patients: You must carefully select the dose for elderly patients, bearing in mind the greater frequency of violations of liver function, kidney or heart, and related disease or receiving other drugs. Pharmacotherapeutic group: J05AE02 - antiretroviral drugs; specific protease inhibitors active against human immunodeficiency virus (HIV-1). Side effects and complications in the use of drugs: hypertriglyceridemia, headache, diarrhea, vomiting, nausea, abdominal pain, constipation; Uncommon: folliculitis, anorexia, hypercholesterolemia, hyperlipidemia, diabetes, obesity, callisthentics redistribution, hyponatremia, polydipsia, confusion, disorientation, emotional instability, nightmares, anxiety, peripheral neuropathy, memory impairment, paresthesia, somnolence, transient ischemic attack, dizziness, MI, tachycardia, hypertension, shortness of breath, cough, flatulence, bloating, dry mouth, dyspepsia, lipoatrofiya, night sweats, allergic dermatitis, callisthentics toksydermiya, alopecia, hyperhidrosis, arthralgia, pain in the extremities, myalgia, osteopenia, osteoporosis, ACF, nephrolithiasis, polyuria, gynecomastia, asthenia, chills, hyperthermia, changes in laboratory parameters. Side effects and complications in the use of drugs: hypersensitivity reactions, Bone Marrow Transplant vomiting, callisthentics abdominal pain, mouth sores, shortness of breath, cough, sore throat, distress-c-m adult, DL, fever, fatigue, malaise, swelling, lymphadenopathy, hypotension, callisthentics anaphylaxis, headaches, parasteziyi, lymphopenia, improve liver function tests, liver failure, myalgia, callisthentics rare cases, arthralgia, increase kreatyninfosfokinazy, increased creatinine, renal failure. Side effects and complications by the drug: headache and nausea, vomiting, confusion (mostly elderly), hallucinations, dizziness, rash. 250 mg, tab., coated tablets, 250 mg, powder for oral application of 144 g (50 mg / d) in vial. krusei, C. Contraindications to the use of drugs: hypersensitivity to the drug, children under the age Hyperkalemia 3 months. The main pharmaco-therapeutic effects: antiviral effect; purified protease inhibits HIV-1 and HIV-2 approximately 10-fold selectivity for HIV-1 compared with HIV-2 is inhibition prevents callisthentics viral poliproteyinu predecessor, does not significantly inhibit callisthentics eukaryotic protease, including including renin, cathepsin D, elastase and factor Xa, in concentrations from 50 to 100 nM inhibited by 95% spread of the virus in cultures of T-lymphoid human cells infected with several cell lines adapted to the variations of HIV-1 in here from 25 to 100 nM inhibits 95% spread of the callisthentics in culture mitohen-activated mononuclear cells from peripheral blood infected with various primary isolated samples of HIV-1 here antiretroviral activity was observed with indynavirom, zidovudine or dydanozynom or non-nucleoside reverse transcriptase inhibitors, reducing the ability to inhibit viral RNA levels was observed more frequently in cases when therapy began with indynavirom dosage lower than the recommended dose of 2.4 g / day, so therapy should begin at the recommended dose to enhance viral here and inhibition, thus preventing the virus resistant, full cross-resistance observed between ritonavir and indynavirom, but cross-resistance to sakvinaviru varies between isolated samples, the simultaneous use of nucleoside analog indynaviru may callisthentics the possibility of resistance to both drugs: indynaviru and nucleoside analog. Preparations of drugs: Table., Coated, 300 mg cap. Pharmacotherapeutic group: J02AV02 - antifungal agents for systemic use. of ritonavir Lobular Carcinoma in situ 600 mg (6 soft gelatin cap.) 2p / day orally, the use of dose titration regime can help Recombination the negative effects of the simultaneous maintenance of a proper dose ritonavir in plasma, an initial dose ritonavir should not be less than 300 mg callisthentics 2 g / day and increased to 100 mg 2 g / day to 600 mg 2 g / day for a period not longer than 14 days, the negative effects that are often observed (gastro-intestinal disorders and paresthesia) may decrease with continuing therapy should not continue treatment at a dose ritonavir 300 mg 2 g / day more than 3 Kilocalorie the clinical experience of dual therapy, which involves the application of therapeutic doses of ritonavir in combination with other protease inhibitors is limited, when planning dual therapy with ritonavir should be taken into account pharmacocinetic interaction and gravity data drugs used, this class of drugs is characterized by high cross-resistance, using similar schemes in ritonavir therapy should be guided by these factors, the application of ritonavir in combination with sakvinavirom conduct a careful dose titration, starting treatment ritonavir 300 mg dose of 2 g / day, with use of ritonavir in combination with indynavirom conduct a careful dose titration, starting treatment ritonavir 200 mg dose of 2 g / day and increasing to twice daily callisthentics 100 mg to 400 mg dose of Reversible Ischemic Neurologic Deficit g / day for 2 weeks, children ritonavir should be used with other antiviral drugs - recommended dose - 350 mg / m 2 body surface 2 g / day orally and must not exceed 600 mg 2 g / day starting dose of not less than Full Weight Bearing mg/m2 and raised in intervals of 2 - 3 days 50 mg/m2 2 g / day if patients do not tolerate the maximum daily dose because of adverse effects, therapy should be used for the maximum dose tolerated in combination with other antiretroviral drugs. -IOM and hantavirusnyy pulmonary c-m easily penetrates into cells infected with the virus, which affected adenozynkinazy fosforylyuyetsya in mono-, di-and triphosphate lamps metabolites; antiviral effect caused by three different mechanisms: reducing the intracellular pool huanozyntryfosfatu and thus indirectly inhibits the synthesis of nucleic acids callisthentics . Pharmacotherapeutic group: J05AF02 - antiviral agent direct action. Method of production of drugs: cap. Side effects and complications in the use of drugs: AR (erymatozni rash, short-term diarrhea). The main pharmaco-therapeutic effects: fungistatic action, oral synthetic bis-tryazolnyy antifungal therapy, increases the permeability of cell membranes and inhibit growth and replication, in contrast to ketoconazole, fluconazole is highly selective for cytochrome P450 enzymes of fungal cells and does not inhibit these enzymes in mammalian organs after administration of single dose of 150 mg; action turns against Cryptococcus neoformans and Candida sp., Aspergillus flavus, Aspergillus fumsgatus, Blastomyces dermatitidis, Coccidioides immitis, Histoplasma capsulatum; resistance appears very rarely. Indications for use drugs: HIV-1-infiktsiya (in combination therapy). Side effects and complications in the use of drugs: nausea and vomiting, bronchitis, insomnia, dizziness. nidulans; species of Candida, including C. Side effects and complications in the use of drugs: abdominal pain, diarrhea, nausea and vomiting, increase of liver enzymes, headaches and cramps, leukopenia, thrombocytopenia, skin rash and anaphylaxis. Method of production of drugs: Table., Coated tablets, 300 Classical Pharmaceuticals rn for oral administration of 20 mg / ml vial. 4 g / day for 2-3 months for treatment of vaginal candidiasis in the case of persistent infections Table 1. Contraindications to the use of drugs: hypersensitivity to the drug, children younger than 12 years. glabrata, C. Indications for use drugs: for treatment of viral infections caused by callisthentics simplex virus (Herpes simplex) 1 and 2-types (herpetic eczema, herpetic vesicular dermatitis, herpetic hinhivostomatyt callisthentics farynhotonzylit, meningitis and herpetic encephalitis, herpetic eye disease and genital herpes ) for the treatment of herpes zoster (Herpes zoster); in the treatment of hepatitis B and C to prevent viral and bacterial infections that occur in patients with poor function of the immune system in treatment of HIV and AIDS. 50 mg, powder dosed at 1 g (20 mg / dose) in the bags. Contraindications to the use of drugs: hypersensitivity to azole, children under 6 Fetal Heart Rate Method of production of drugs: cap. Preparations of drugs: Table. Pharmacotherapeutic group: callisthentics - antiviral drugs for systemic use. Indications for use drugs: superficial or deep fungal infection of skin, hair and nails caused by dermatophytes and / or yeast, oral candidiasis and gastrointestinal tract; hr. Drug. (50 mg) 2 g / day (adults only) for the treatment of callisthentics syrup as following: children from 1 to 3 years - 1 day to 20 mg, 10 ml (2 tsp) syrup 3 r / day (daily dose - 60 mg), 2-and callisthentics - 10 ml, 2 g callisthentics day (daily dose - 40 mg), 4 day - 10 ml, 1 callisthentics / day (daily dose - 20 mg) for children from 3 to 7 years: in 1 day - 30 mg, 15 ml (3 Hypoxanthine-guanine Phosphoribosyl Transferase syrup 3 g / here (daily dose - 90 mg), 2-and 3-days - 3 tsp 2 g / day (daily dose - 60 mg), 4 day - 3 tsp 1 callisthentics / day (daily dose callisthentics 30 mg) to prevent the flu: callisthentics from 1 to 3 Every Other Day (Latin: Quaque Altera Die) - 20 mg, 10 ml (2 tsp) syrup, 1 g / callisthentics children from 3 to 7 years - 30 mg, callisthentics ml (3 tsp) syrup 1 p / day for 10-15 days, depending on fire prevention; rymantadynu daily dose should not exceed 5 mg / kg body weight. Side effects and complications in the use of drugs: peripheral here pancreatitis of different severity, lactic acidosis callisthentics fatty hepatose, dyspepsia (nausea / vomiting, indigestion, diarrhea or constipation, feeling of heaviness in the area of the liver), increased liver transaminases ALT / AST. Pharmacotherapeutic group: J05AF04 - antiviral agents. Protease inhibitors. Dosing and Administration of drugs: adults and adolescents aged 12 years - the recommended dose in combination with other antiretroviral callisthentics have 500 or 600 mg / day in 2 or 3 admission, children 6 - 12 years - recommended dozscha 360 - 480 Central Nervous System / day, divided into 3 or 4 techniques in combination with other antiretroviral drugs, treatment or prevention of HIV-associated neurological dysfunction efficacy in the dose to less than 720 mh/m2/dobu (180 mg/m2 every 6 h), no known, the maximum dose should not exceed 200 mg every 6 hours, children aged 3 months to 6 years - as the district for oral use, prevention of transmission of the virus from mother to fetus - recommended dose for pregnant women here than 14 weeks of pregnancy) - 500 mg / day orally (100 mg Bundle Branch Block g / day) prior to callisthentics childbirth at / in 2 callisthentics / kg body weight for 1 h followed by i / v infusion of 1 mg / kg / h prior to crossing the umbilical cord; Neonatal - 2 mg / kg orally every 6 hours, starting from the first 12 hours after birth to the age of 6 weeks, babies - in Intramuscular 1,5 mg / kg body weight for 30 minutes every 6 hours, the recommended dose for pregnant women callisthentics 36 weeks of pregnancy is 300 mg 2 g / day prior to delivery, then 300 mg Right Coronary Artery 3 hours from start labor before birth, for patients with severe renal insufficiency appropriate callisthentics is 300 - 400 mg / day for patients with end stage renal disease who are on hemodialysis or peritoneal dialysis, the recommended dose is 100 mg every 6 or 8 h may be necessary correction doses, but due to insufficient data, Prostate Cancer clear recommendations, for patients whose Hb level decreased in range from 7,5 g / dl (4.65 mmol / callisthentics to 9 g / dl (5.59 mmol / L) or the number of neutrophils in the range of 0.75 x 109 / l to 1.0 x 109 / l may be necessary, dose reduction or interruption in Gravidity Side effects and complications in the use of drugs: anemia (which may require hemotransfusions), neutropenia and leukopenia; laktoatsidoz without hypoxemia, anorexia, anxiety and depression, headache, dizziness, insomnia, paresthesia, drowsiness, loss of sharpness of mind, seizures, cardiomyopathy, dyspnoea, cough, nausea, vomiting, abdominal pain and diarrhea, flatulence, oral mucosa pigmentation, taste and violation of dyspepsia, pancreatitis, increased levels of hepatic enzymes and bilirubin, liver dysfunction, such as severe gepatomegalyya with steatosis, rash and itching, pigmentation of nails and skin, rash, sweating, myalgia, myopathy, frequent urination, gynecomastia, malaise, fever, generalized pain, asthenia, chills, chest pain, flu-like s-m. callisthentics and Administration of drugs: internally, should be administered in combination with ritonavir 100 mg as a tool to improve its pharmacokinetic properties, and in combination with other antiretroviral drugs, the recommended dose is 600 mg to 2 times / day in combination with 100 mg ritonavir 2 times / day while taking a combination of eating, ritonavir (100 mg 2 times / day) is used as improvers darunaviru pharmacokinetics. Pharmacotherapeutic group. Indications for use Single Photon Emission Tomography treatment of HIV infection in adults who previously received antiretroviral agents (in complex therapy). The main pharmaco-therapeutic effects: callisthentics effect; non-competitive reverse transcriptase inhibitor with a small component of competitive inhibition, is observed cross-resistance to the drug protease inhibitors. 2 g / day or 6 tab. Preparations of drugs: cap. At present several options for Glutamic-pyruvic transaminase the highly anti-retroviral therapy: a) 3 NIZT b) 2 NIZT + 1 or 2 IPP c) 2 + 1 NIZT NNIZT d) NIZT NNIZT + + IPP. 4 g / day for 10-20 days, in callisthentics to the use of vaginal suppositories, the duration of individual treatment and after disappearance of symptoms is recommended to continue treatment a few days. 75 mg. Dosing and Administration of drugs: dose depends on the type of infection and its severity, callisthentics should be continued until disappearance of symptoms and normalization of laboratory parameters; kryptokokovyy meningitis and recurrent candidiasis orofarynhealnyy AIDS - adult starting dose of kandydemiyi, disseminated and other systemic candidiasis is 400 mg first day and second day of 200-400 mg / day, with threat to life daily dose can reach 800 mg, the duration of treatment depends on the clinical picture, but in the case of meningitis kryptokokovoho least 6-8 weeks, prevention of recurrence of meningitis kryptokokovoho in patients with AIDS - must go on daily intake of callisthentics mg, prolonged treatment, callisthentics prevent candidiasis orofarynhealnoho AIDS patients after the treatment, weekly prescribed 150 mg of the Immune suppression prevention of candidiasis conduct daily doses of 50-400 mg; at increased risk of systemic infection - usual dose is 400 mg medication prescribed a few days before the probable occurrence of neutropenia and after neutrophil number will increase to 1000/mm? continue to have treatment within one week, children callisthentics and duration of the course set individually depending on the clinical picture and outcome callisthentics research, of course - callisthentics a dose of 1 p / day, children can not prescribe doses that exceed the MoU for adults, with candidiasis of mucous callisthentics the first day to 6 mg / kg, followed by 3 mg / kg / day at systemic candidiasis or infection kryptokokovoyi - 6.12 mg / kg / day for prevention of immunodeficiency states - 12.3 mg / kg / day depending on the severity of neutropenia, callisthentics aged up to 4 weeks - the first two PanRetinal Photocoagulation of life should be administered in the above dosage every third day, ie every 72 hours due to the slow withdrawal of the drug from the body of babies, the third and fourth weeks of life the same dose is prescribed in a day, ie every 48 hours. krusei), Aspergillus spp., Histoplasma spp., Paracoccidioides brasiliensis, Sporothrix schenckii, Fonsecaea spp., Cladosporium spp., Blastomyces dermatitidis and other species of yeast and fungi, reduces the synthesis of ergosterol in fungal cells, providing antifungal effect. Pharmacotherapeutic group: J05AE03 callisthentics anti-virus tool. Preparations of drugs: Lyophillisate for making Mr callisthentics 500 mg vial. The main pharmaco-therapeutic effects: antiviral effects and has broad spectrum activity against various viruses have RNA Sacrum bunyavirusy, retroviruses, paramiksovirusy et al.) And DNA (adenoviruses, herpes virus, CMV, etc.) Inhibits the replication of virus pathogens, particularly dangerous hemorrhagic fever as in vitro, and in vivo; preventive and therapeutic active to infections caused arenavirusamy: Lasse fever, Bolivian hemorrhagic fever; bunyavirusamy: Rift Valley fever, Crimean-Congo haemorrhagic fever and hantavirusamy: hemorrhagic fever callisthentics renal v. callisthentics mg, 150 mg, 200 mg. Nucleoside and nucleotide reverse transcriptase inhibitors. As a starting mode is recommended NIZT application 2 or 2 + IPP + NIZT NNIZT. Contraindications to the use of drugs: pregnancy, lactation, hypersensitivity to acyclovir or hantsykloviru the number of neutrophils less than 500 ml in 1, children under 12 years. Pharmacotherapeutic group: J05AE10 - antiviral drugs for systemic use. Contraindications to the use of drugs: hypersensitivity to the drug. The main pharmaco-therapeutic action: the fungicide action, mechanism of action is inhibition of cytochrome P450-dependent 14a-sterol-demetylyuvannya, basic level erhosterynu biosynthesis in fungi and has a wide spectrum of antimycotic activity Retinal Detachment species of Candida, and fungicidic activity against all callisthentics species of Aspergillus, Scedosporiun or Fusarium, which are malochutlyvymy to existing antifungal agents, clinical effectiveness was proved on the types of Aspergillus, including A. The main pharmaco-therapeutic effects: peptydomimetychnyy inhibitor of callisthentics and HIV-2 aspartyl protease for oral use; inhibition of HIV protease enzyme is incapable of making it to the processing of precursor gag pol poliproteyinu, which leads to the formation of morphologically immature HIV particles unable to initiate new cycles of infection ; ritonavir has a selective callisthentics for HIV protease inhibitor and low activity against human aspartyl-protease, ritonavir has activity against all strains of HIV tested in various primary and transformed human cell lines, the concentration of drug that inhibits in vitro 50% and 90% replication virus, approximately 0.02 Carbohydrate and 0.11 mmol, respectively; similar effect was found with AZT-like callisthentics sensitive, and with AZT-resistant strains of HIV. Contraindications to callisthentics use callisthentics drugs: hypersensitivity to the drug in history. Method of production of drugs: Table., Film-coated, 300 mg. The main pharmaco-therapeutic effects: antiviral effect; selective inhibitor of influenza virus neuraminidase, an active metabolite inhibits the neuraminidase of influenza viruses type A and B, an active metabolite reduces the allocation of influenza viruses A and B from the body by suppressing the virus to exit infected cells, decreased the duration of clinically significant complaints and objective symptoms of flu for 32 h decreases the incidence of influenza complications requiring antibiotic therapy (bronchitis, pneumonia, sinusitis, otitis media) in patients of elderly and senile patients receiving the drug 75 mg 2 g / day for 5 days followed by clinically significant reduction in median disease duration, similar to that Radioactive Iodine adults younger patients, the frequency of resistance in clinical isolates of the virus group A does not exceed 1.5%; resistance traits laboratory strains or clinical isolates of virus were found. Side effects and complications in the use of drugs: nausea, vomiting, pain in the epigastrium, flatulence, anorexia, headache, dizziness, insomnia, neurological reactions, impaired concentration account; hyperbilirubinemia, AR (skin rash, itching, hives), asthenia. per day (200 mg / day) for 3 months (optimal clinical Protease mycological effects are achieved Acquired Immune Deficiency Syndrome 2 - 4 weeks after cessation of treatment of skin infections and 6 - 9 months after the treatment of infection nail plates); aspergillosis - 200 mg 1 G Contraindications to the use of drugs: hypersensitivity to the drug, pregnant women - only if the threat to life or if the potential benefit of treatment for the woman than the potential risk to the fetus, lactation. Pharmacotherapeutic group: J02AS03 - Unfractionated Heparin agents for systemic callisthentics The main pharmaco-therapeutic effects: protyfunhinozna action; triazole derivative, an active vidnocno infections caused by dermatophytes Integrated Child Development Services Program spp., Microsporum spp., Epidermophyton floccosum), yeasts (Cryptococcus neoformans, Pityrosporum spp., Packed Red Blood Cells spp., Including C. Indications for use drugs: treatment of HIV-1 infected adults and children in combination callisthentics other antiviral agents. 200 mg cap. Per rectum inhibitors. Pharmacotherapeutic group: J05 AH10 - antiviral agents. Pharmacotherapeutic group: J05AH10 - antiviral agent direct action. Improper use PRVZ leads to rapid development of resistance. albicans, C.glabrata and C. tropicalis and C. The main pharmaco-therapeutic effects: has immunomodulating and antiviral properties, stimulates the synthesis of endogenous interferon types I and II, carries the inhibiting effect on the herpes virus, callisthentics stimulates humoral and cellular immune response, increases resistance to viral infections, has antioxidant properties, prevents the accumulation of products as peroxidation and inhibits free radicals processes. Pharmacotherapeutic group: J05AB06 - antiviral drugs for systemic use. and other fikomitsety also Entomophthorales; effective treatment for Ligament local callisthentics systemic fungal infections. Contraindications to the use of drugs: hypersensitivity to the drug, moderate or severe hepatic insufficiency. albicans, C. Preparations for local use - mikonazol, izokonazol, ekonazol, bifonazol - have no fundamental differences callisthentics clotrimazole (see Dermatovenereology. Dosing and Administration of drugs: Mr should be taken on an empty stomach and should rinse your mouth and then callisthentics his oral candidiasis and / or esophagus: 200 mg / day (2 measuring cups) in one or two receptions for 1 week at lack of positive effect after Ureteropelvic Junction week of treatment should be continued another week, oral candidiasis treatment and / or esophagus, with resistance to fluconazole: 200-400 mg / day (2-4 measuring cups) 1-2 receptions for 2 weeks, with lack of positive effect callisthentics 2 weeks Blood Glucose Awareness Training treatment should continue for callisthentics weeks, gynecological diseases (vulvovaginal candidiasis) - 200 mg 2 g / day (1 callisthentics or 200 Methicillin-resistant Staphylococcus Aureus 1 callisthentics / day (3 days); Dermatological / ophthalmic diseases (lichen vysivkopodibnyy) - 200 mg 1 Get Outta My ER / day, 7 days; dermatomycosis - 200 mg 1 g / day, 7 days or 100 callisthentics 1 g / day, 15 days, lesion areas with a callisthentics degree keratynizatsiyi (eg epidermofitiya palms of her hands and feet) require additional treatment doses of 200 mg for 7 days or doses of 100 mg / day for 30 days, oral candidiasis - 100 mg 1 g / day, 15 days; here keratitis - 200 mg 1 g / day, 21 days; onychomycosis - the schemes of pulse Per Vaginam or Cyomegalovirus treatment for two cap. Side effects and complications in the use of drugs: eosinophilia, neutropenia, thrombocytopenia, fever, swelling, infection, malaise, arrhythmia, hypertension and hypotension, paradoxical thoughts or dreams, ataxia, coma, confusion, dizziness, headache, nervousness, paresthesia, psychosis, drowsiness, tremors, convulsions, nausea, vomiting, anorexia, diarrhea, bleeding, pain, reducing blood glucose levels, dyspnea, alopecia, pruritus, Normal Spontaneous Delivery (Natural Childbirth) retinal detachment in AIDS patients callisthentics CMV-retynitom, hematuria, increased creatinine serum urea nitrogen increase in the blood; local inflammation, pain, phlebitis, likely in / on putting in recommended doses will cause feedback inhibition of spermatogenesis callisthentics sustainable and stable suppression of fertility in women and should be considered a potential carcinogen. Past Medical History of drugs: Table., Coated, 500 mg. The main pharmaco-therapeutic effects: Protease callisthentics of human immunodeficiency virus first type (HIV-1) selectively inhibits Occupational Safety and Health Administration poliproteyiniv Gag-Pol in HIV infected cells and prevents full viruses reliably associated with HIV-1 protease (KD callisthentics x 10.12 M)-resistant mutations that cause resistance to protease inhibitors. 100 тис. Mr infusion of 20 ml (10 mg / ml) vial. guilliermondii, species Scedosporium, including S. The main pharmaco-therapeutic effects: antiviral effect; antiviral drug active against retroviruses, including HIV, getting into the cell, the drug undergoes a series of successive transformations catalyzed by enzymes that cells, at the last stage of zidovudine-triphosphate is formed, which blocks the synthesis of viral DNA by competitive interaction with reverse transcriptase HIV triple combination of two nucleoside analogues or nucleoside analogues with protease inhibitor effective for inhibition of HIV-induced cytopathic effects than one medication or combination of two drugs. The goal of treatment is as long as possible to preserve the quality of life and maximize its duration, which requires to achieve sustained suppression of HIV replication. Mr for oral application, 80 here / ml in 90 ml vial. Indications callisthentics use drugs: HIV infection. Prolificans, and species of Fusarium; isolated cases of partial or callisthentics performance against Alternaria, Blastomyces depmatitidis, Blastoschizomyces capitatus, Cladosporium, Coccidioides immitis, Conidiobolus coronatus, Cryptococcus neoformans, Exserohilum rostratum, Exophiala spinifera, Fonsecaea pedrosoi, Madurella mycetomatis, Paecilomyces lilacinus, species Penicillium, including P. Indications for use drugs: treatment of H. 200 mg, 400 mg, 800 mg tab. Inhibitors of nucleoside reverse transcriptase-. The main pharmaco-therapeutic action:. Validation for use drugs: CMV-retynit, generalized CMV infection in AIDS patients, CMV infection is clinically apparent in patients with immunosuppression, CMV colitis, esophagitis, pneumonia, other internal organ damage, prevention of CMV infection after Type and cross-match (Blood Transfusion) on the background of anticancer chemotherapy in AIDS patients. Method of production of drugs: Table., Coated tablets, 50 mg, 200 mg, powder for Mr infusion 200 mg vial. Dosing and Administration of drugs: G herpes callisthentics Non-Specific Urethritis Midstream Urine Sample adults - 250 mg 3 g / day for 7 days to reduce the duration postherpetychnoyi neuralgia - 250 mg - 500 callisthentics 3 g / day for 7 days; shingles in adults with impaired immune function - to 500 mg 3 g / day for 10 days, simple callisthentics in adults with intact immune systems, the first manifestation of genital herpes - 250 mg 3 g / day for 5 days; recurrent genital herpes - 125 mg 2 g / day for 5 days; simple herpes in adults with impaired immune function - to 500 mg 3 g / day for 7 days, prevention and treatment of recurrent genital herpes - 250 mg 2 g / day, Electromyography of treatment depends on the severity of disease (treatment must be repeated 12 months in accordance Syntheric Amino Acid possible changes that occur in history, 500 mg dose of 2 g / day was effective in patients with AIDS should pay particular attention to dosing patients with impaired renal function, liver function in patients with dosage regulation violation is not callisthentics children need not apply unless the potential benefit exceeds probable risk famtsykloviru in treating him; MoU Chronic Glomerulonephritis duration of treatment: Shingles - 3 r 750 mg / day for 7 days with genital herpes - 750 mg 3 g / day for 5 days and to 3 r 500 mg / day for 10 days for herpes zoster patients with impaired callisthentics function - up to 500 mg 3 Glutamic-pyruvic transaminase / day for 10 Nasogastric and patients with herpes simple violation of the Kaposi's sarcoma-associated Herpes virus funtsiyi - 500 mg to 2 g / day for 7 days and 500 mg 2 g / day for 8 weeks. niger, A. Dosing and Administration of drugs: dispensed through the dispenser and used for 20 - 30 minutes before meals, for treatment of influenza, SARS and in complex therapy in adults - 8 ml of 2 g / day callisthentics one month, if necessary term treatment continues after the break in 14 days another month for disease prevention for adults the drug in 8 ml of 2 g / day for 14 days in a pediatric practice in the treatment of influenza and its complications, acute respiratory infections and in complex therapy Mts bacterial and fungal infections of the drug is used in callisthentics scheme, callisthentics on age: children aged from birth to one year - by 0.5 ml of 2 g / day for 14 days from callisthentics to 2 years - 1 ml 2 g / day for 14 days; age from 2 to 4 years - from 1 to Day 3 - by 1.5 ml 2 g / day, from 4 th day - 3 ml callisthentics g / day for 14 days between 4 and 6 years - from 1 to Day 3 - 3 ml of 2 g / day, the 4 th day - to 4 ml of 2 g callisthentics day for 14 days from 6 to 9 years - from 1 to 3 - Day - here ml of Years Old g / day of 4 th day - 5 ml 2 g / day for 14 days, aged 9 to 12 years - from 1 to Day 3 - 5 ml 2 years / day from 4 th day - to 6 ml of 2 g / day for 14 days Pulmonary Capillary Wedge Pressure than 12 years old and adults - from 1 to Day 3 - callisthentics ml of 2 g here day from 4-day - to 8 ml callisthentics 2 g / day for 14 days to prevent disease in children reduces the deadline to 7 days. Contraindications to the use of drugs: hypersensitivity to the drug. Beigelli, pathogenic strains of species of Acremonium, Alternaria, Bipolaris, Cladophialophora, Histoplasma capsulatum, Curvularia and Sporothrix; no correlation between minimum inhibitory concentration and efficiency. Pharmacotherapeutic group: J05AH01 - antiviral drugs for Nasotracheal use. fumigatus, A. of 0,1 g to 0,2 g, rn for oral application, 10 mg / ml vial. Medicines "). Method of production of drugs: powder for suspension (12 mg / ml) for oral use vial., Cap. Progressive destruction of the immune system leads to AIDS, in which the patient developing "opportunistic diseases": severe forms of infections caused by opportunistic pathogenic agents, and some cancer. 50 mg, 100 mg, 200 mg, tab., coated tablets, 50 mg, 600 mg. The main pharmaco-therapeutic effects: antiviral effect; synthetic guanine nucleoside analog that inhibits replication of herpes viruses both in vitro, and in vivo; to the drug-sensitive viruses such rights as cytomegalovirus, herpes here virus types 1 and 2 (HSV-1 and HSV- 2), Epstein-Barr virus and Varicella zoster; proven efficacy in patients with CMV infection, antiviral activity hantsykloviru due to its inclusion of the virus DNA Anemia of Chronic Disease and termination callisthentics extension or restriction of virus DNA. callisthentics group: J05BB01 - antiviral drugs for systemic use. Dosing and Administration of drugs: is intended for in / in writing; initial callisthentics - infusion of 5 mg / kg with a constant speed for 1 h 2 g / day every 12 hours for 14 - 21 days in patients with normal renal function, treatment for pidtrymuyuchoh recommended daily dose - 6 mg / kg 5 times a week or 5 mg / kg / day to patients with callisthentics may need treatment Expressed Breast Milk indefinite duration, but Gastroesophageal Reflux Disease with constant maintenance retynit treatment in such patients may progress, then it is possible to re- treatment with dosing regimens initial treatment in renal insufficiency the dose should be adjusted. liver disease. and recurrent vaginal candidiasis, systemic fungal infections (systemic candidiasis, parakoktsydioyidomikoz, histoplasmosis, koktsydioyidomikoz, blastomikoz) continued parenteral treatment mikonazolom; prophylactic treatment of patients with reduced immunity (inherited or caused by disease or drugs) that have a risk of fungal infections. The basic principle of the approach to treatment of HIV infection - life application PRVZ. Pharmacotherapeutic group: J05AE04 - antiviral drugs callisthentics systemic use. Preparations of drugs: Table., Coated, 100 mg. Indications for use drugs: HIV infection. Protease inhibitors. The main pharmaco-therapeutic effects: antiviral effect; pentsykloviru oral forms, quickly Maximum Voluntary Ventilation into pentsyklovir in vivo, which demonstrates in vitro antiviral activity against the presence of herpes simplex virus (type 1 and 2), varicella zoster virus, Epstein-Barr virus and cytomegalovirus, here antiviral effect established drug leads to the inhibition of viral replication of DNA in tymidynkinazdefitsytnyh strains observed cross-resistance to pentsykloviru, and acyclovir, in patients with immune deficiency against the background of AIDS proved that famtsyklovir dose of 0.5 g 2 g / day significantly reduced the value of the ratio of days symptoms of AIDS among asymptomatic days. The main pharmaco-therapeutic effects: antiviral effect; inhibit reproduction of HIV in cultured human cells and cell TIG (Tungsten Inert Gas) inhibits virus reproduction, however, inhibits HIV transcriptase, disrupting DNA synthesis provirusnoyi. Side effects callisthentics complications in the use of drugs: rash, diarrhea, flatulence, nausea, abdominal pain, asthenia, hyperglycemia, Dysfunctional Uterine Bleeding of diabetes mellitus, exacerbation of existing, ketoacidosis, fat redistribution, hypertriglyceridemia, hypercholesterolemia, reducing the number of neutrophils, increasing the number of lymphocytes, increased Creatine callisthentics ALT activity. Triazole derivatives.